PRKAA1 and cancer: Additional multi-cancer agents such as LY3023414, a PI3K/mTOR inhibitor; zotatifin, an eIF4A inhibitor affecting translation; and sirolimus, which inhibits mTORC1 downstream of AMPK activation, are being explored [63–65].